Find policies, billing codes, payers, states, and providers
CPT 0022U: Oncomine™ Dx Target Test for NSCLC and Cholangiocarcinoma
CPT code 0022U designates the Oncomine™ Dx Target Test, a proprietary molecular diagnostic assay that profiles tumor tissue for gene sequence variants and rearrangements in non–small cell lung cancer (NSCLC) and cholangiocarcinoma. As a PLA code tied to a single manufacturer's test, it identifies a specific laboratory service used to inform targeted therapy decisions and precision oncology pathways. Nationally, such PLA codes matter because they standardize reporting for unique commercial tests and affect coverage, coding transparency, and claims processing across payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of code purpose and clinical context, typical sites of service, and payer coverage considerations. The publication also summarizes common modifiers associated with laboratory billing, and highlights how PLA designation influences documentation and claims workflows.
The content provides benchmarks and policy context relevant to hospital and outpatient laboratories, oncology practices, and health plan administrators. It is intended to help billing managers, laboratory directors, and policy analysts understand the clinical role of the assay, where it is performed, and the payer landscape for a nationally used proprietary tumor profiling test.
Customize your policy alerts
Sign up for cpt 0022U policy alerts
Get alerted when payer policies referencing 0022U are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 0022U is a Proprietary Laboratory Analyses (PLA) code that describes the Oncomine™ Dx Target Test by Thermo Fisher Scientific. The test evaluates tumor tissue from patients with non–small cell lung cancer (NSCLC) or cholangiocarcinoma for gene sequence variants and rearrangements that may indicate potential targeted therapies.
Service type: Molecular diagnostic laboratory test (tumor genomic profiling)
Typical site of service: Clinical laboratory or hospital outpatient laboratory, with specimens derived from tumor tissue collected in a prior clinical encounter.